Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

BACKGROUND: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting MS (RRMS) can delay the transition to secondary progression (SP). OBJECTIVE: To compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Tedeholm, H, Lycke, J, Skoog, B, Lisovskaja, V, Hillert, J, Dahle, C, Fagius, J, Fredrikson, S, Landtblom, A-M, Malmeström, C, Martin, C, Piehl, F, Runmarker, B, Stawiarz, L, Vrethem, M, Nerman, O, Andersen, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2013
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652599/
https://www.ncbi.nlm.nih.gov/pubmed/23124789
http://dx.doi.org/10.1177/1352458512463764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652599/
https://www.ncbi.nlm.nih.gov/pubmed/23124789
http://dx.doi.org/10.1177/1352458512463764

Ejemplares similares